Evidence map›Paper›PMID 25586209›Full record

ReviewParasites & vectors2015

Cellulose degradation: a therapeutic strategy in the improved treatment of Acanthamoeba infections.

Sahreena Lakhundi, Ruqaiyyah Siddiqui, Naveed Ahmed Khan

Abstract readReview
In one paragraph

Review in Parasites & vectors, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Encystment and Excystment Processes inPathogens (Basel, Switzerland) · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Biological characteristics and pathogenicity ofFrontiers in microbiology · 2023
    Review
  12. Review
  13. Review
  14. Article
  15. Stable Cellulose Nanofibril Microcapsules from Pickering Emulsion Templates.Langmuir : the ACS journal of surfaces and colloids · 2022
    Article
  16. Stimulation ofFrontiers in cell and developmental biology · 2022
    Article
  17. Article
  18. Article
  19. Pathogens (Basel, Switzerland) · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sahreena LakhundiDepartment of Biological and Biomedical Sciences, Aga Khan University, Stadium Road, Karachi, Pakistan. sahreena.saleem@aku.edu.
Ruqaiyyah SiddiquiDepartment of Biological and Biomedical Sciences, Aga Khan University, Stadium Road, Karachi, Pakistan. ruqaiyyah.siddiqui@aku.edu.
Naveed Ahmed KhanDepartment of Biological and Biomedical Sciences, Aga Khan University, Stadium Road, Karachi, Pakistan. naveed5438@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acanthamoeba is an opportunistic free-living amoeba that can cause blinding keratitis and fatal brain infection. Early diagnosis, followed by aggressive treatment is a pre-requisite in the successful treatment but even then the prognosis remains poor. A major drawback during the course of treatment is the ability of the amoeba to enclose itself within a shell (a process known as encystment), making it resistant to chemotherapeutic agents. As the cyst wall is partly made of cellulose, thus cellulose degradation offers a potential therapeutic strategy in the effective targeting of trophozoite encased within the cyst walls. Here, we present a comprehensive report on the structure of cellulose and cellulases, as well as known cellulose degradation mechanisms with an eye to target the Acanthamoeba cyst wall. The disruption of the cyst wall will make amoeba (concealed within) susceptible to chemotherapeutic agents, and at the very least inhibition of the excystment process will impede infection recurrence, as we bring these promising drug targets into focus so that they can be explored to their fullest.

Indexed as

AcanthamoebaAmebiasisAnimalsCellulasesCelluloseHumansCellulasesCellulose

Identifiers

PMID25586209
PMCPMC4300153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.